Genocea Biosciences

$3.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (+5.77%) Today
-$0.20 (-6.06%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell GNCA and other stocks, options, and ETFs commission-free!

About GNCA

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA. The listed name for GNCA is Genocea Biosciences, Inc. Common Stock.

CEO
William D. Clark
Employees
59
Headquarters
Cambridge, Massachusetts
Founded
2006
Market Cap
192.83M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
981.84K
High Today
$3.41
Low Today
$3.08
Open Price
$3.13
Volume
402.29K
52 Week High
$5.75
52 Week Low
$1.10

GNCA Earnings

-$0.66
-$0.50
-$0.34
-$0.18
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.21 per share
Actual
-$0.18 per share
Replay Earnings Call

You May Also Like

EXG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure